亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial

医学 蛋白尿 安慰剂 肾功能 肾脏疾病 内科学 糖尿病 临床终点 临床试验 肌酐 泌尿科 2型糖尿病 外科 内分泌学 病理 替代医学
作者
Dick de Zeeuw,Ronny Renfurm,George L. Bakris,Peter Rossing,Vlado Perkovic,Fan Fan Hou,Masaomi Nangaku,Kumar Sharma,Hiddo J.L. Heerspink,Alberto García-Hernández,Tobias E. Larsson
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:6 (12): 925-933 被引量:48
标识
DOI:10.1016/s2213-8587(18)30289-4
摘要

Background Many patients with diabetic kidney disease have residual albuminuria and are at risk of disease progression. The ALBUM trial investigated the efficacy of a novel, orally active inhibitor of vascular adhesion protein-1, ASP8232, compared with placebo for reducing albuminuria in individuals with type 2 diabetes and chronic kidney disease. Methods In this randomised, double-blind, placebo-controlled phase 2 trial, we randomly assigned individuals (aged 18–85 years) from 64 clinical sites in nine European countries to receive ASP8232 40 mg or placebo orally once daily for 12 weeks using a web-based randomisation schedule (block size 4), stratified by country. Eligible patients had a urinary albumin-to-creatinine ratio (UACR) of 200–3000 mg/g, an estimated glomerular filtration rate of at least 25 mL/min per 1·73 m2 but lower than 75 mL/min per 1·73 m2, HbA1c less than 11·0% (97 mmol/mol), and stable treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and antidiabetic medication for 3 months or more. The primary endpoint was mean change from baseline to week 12 in log-transformed first morning void UACR, which was assessed in all patients who received at least one dose of study drug and had at least one post-baseline UACR measurement (full analysis set). Safety was assessed in all patients who received at least one dose of study drug. Participants and investigators were masked to treatment allocation. This trial is registered with ClinicalTrials.gov, number NCT02358096. Findings 125 participants were randomly assigned to receive ASP8232 (n=64) or placebo (n=61), of whom 120 (60 in each group) were included in the full analysis set; all participants were assessed for safety endpoints. At 12 weeks, UACR decreased by 17·7% (95% CI 5·0 to 28·6) in the ASP8232 group and increased by 2·3% (−11·4 to 18·1) in the placebo group; the placebo-adjusted difference between groups was −19·5% (95% CI −34·0 to −1·8; p=0·033). 39 (61%) patients in the ASP8232 group and 34 (56%) patients in the placebo group had a treatment-emergent adverse event, of which 16 in the ASP8232 group and four in the placebo group were drug-related. The most frequently reported adverse events that were possibly drug-related in the ASP8232 group were renal impairment (five patients) and decreased eGFR (three patients); in the placebo group, no single drug-related treatment-emergent adverse event was reported by more than one participant. Interpretation ASP8232 is effective in reducing albuminuria in patients with diabetic kidney disease and is safe and well tolerated. These findings warrant further research to ascertain the effect of ASP8232 on delaying progression of diabetic kidney disease. Funding Astellas.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
所所的应助被atrados采纳,获得10
1秒前
合适书兰完成签到,获得积分10
1秒前
矢思然完成签到,获得积分10
9秒前
受不了12345完成签到,获得积分10
11秒前
www发布了新的文献求助20
11秒前
15秒前
17秒前
19秒前
SimonShaw发布了新的文献求助10
20秒前
www发布了新的文献求助10
24秒前
Jun完成签到,获得积分10
24秒前
SimonShaw完成签到,获得积分10
27秒前
hdrizen完成签到,获得积分10
31秒前
之桃完成签到,获得积分10
34秒前
www完成签到,获得积分10
36秒前
42秒前
彭于晏的应助被李诗语采纳,获得10
44秒前
眯眯眼的板凳完成签到,获得积分10
48秒前
高兴之柔完成签到,获得积分10
54秒前
54秒前
www发布了新的文献求助30
58秒前
英姑的应助被剑K采纳,获得10
1分钟前
1分钟前
爆米花的应助被www采纳,获得10
1分钟前
科研通AI6.4的应助被落寞的祥采纳,获得10
1分钟前
1分钟前
霸气祥完成签到,获得积分10
1分钟前
小马甲的应助被求学的小宸采纳,获得10
1分钟前
剑K完成签到,获得积分10
1分钟前
1分钟前
剑K发布了新的文献求助10
1分钟前
1分钟前
王钢铁完成签到,获得积分10
1分钟前
如意夏寒完成签到,获得积分10
1分钟前
刘心发布了新的文献求助40
1分钟前
落寞的祥发布了新的文献求助10
1分钟前
饱满飞扬完成签到,获得积分10
1分钟前
王聪发布了新的文献求助10
1分钟前
1分钟前
饱满乐安完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179873
求助须知:如何正确求助?哪些是违规求助? 9570055
关于积分的说明 21808206
捐赠科研通 7775540
什么是DOI,文献DOI怎么找? 3433157
关于科研通互助平台的介绍 2557278
邀请新用户注册赠送积分活动 2478846